As per the guidelines by the National Comprehensive Cancer Network (NCCN), anti-PD-L1 immunotherapy (Atezolizumab) is suggested as first-line treatment for NSCLC patients exhibiting PD-L1 expression ≥ 50% or as second-line treatment for those with PD-L1 expression ≥ 1% (3). Here, CD274 is linked to non-small cell lung carcinoma.